---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-108324"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T12:16:18.827373+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kyntra Bio reports FY2025 revenue $6.4M, net loss $58.2M; cash $109.4M into 2028

## Summary
- Full yr 2025 revenue from cont ops $6.4M (vs $29.6M in 2024); net loss $58.2M (vs $153.1M).
- Cash, equivalents, investments, and receivables $109.4M as of Dec 31, 2025; runway into 2028.
- Phase 2 monotherapy trial of FG-3246 in mCRPC enrolling; interim analysis expected 2H 2026.
- Phase 3 protocol for roxadustat in LR-MDS anemia submitted to FDA; start targeted 2H 2026.
- Combo trial of FG-3246 + enzalutamide showed median rPFS 7.0 months; data at ASCO GU 2026.

## SEC filing metadata
- accession: 0001193125-26-108324
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/0001193125-26-108324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/kynb-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-108324
- JSON: https://secwatch.observer/filing/0001193125-26-108324.json
- Plain text: https://secwatch.observer/filing/0001193125-26-108324.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.